Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.6
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 38045004
Gu R, et al. (2023) Methylation of the epigenetic JMJD2D protein by SET7/9 promotes prostate tumorigenesis. Front Oncol 13, 1295613 38045004
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

K427-m1 - JMJD2D (human)
Modsite: AAAVHSSkKPSSTPS SwissProt Entrez-Gene
Orthologous residues
JMJD2D (human): K427‑m1, JMJD2D (mouse): P422‑m1, JMJD2D (rat): A420‑m1
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, modification-specific antibody, mutation of modification site, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), HEK293T (epithelial), LNCaP (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
METHYLTRANSFERASE SETD7 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
METHYLTRANSFERASE SETD7 (human) co-immunoprecipitation, modification-specific antibody, transfection of wild-type enzyme
Downstream Regulation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced, transcription, altered